Announcements Trials
Browse Landscape

Status

Completed 3Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 17INDUSTRY 5NIH 3OTHER_GOV 1

Study Type

Interventional 27Observational 5Expanded_access 3

Sponsor

Conditions

Breast Neoplasms 468Neoplasms 316Carcinoma, Non-Small-Cell Lung 269Prostatic Neoplasms 215Colorectal Neoplasms 208Lung Neoplasms 178Multiple Myeloma 123Melanoma 110Carcinoma, Renal Cell 107Ovarian Neoplasms 94Carcinoma, Hepatocellular 78Pancreatic Neoplasms 69Urinary Bladder Neoplasms 65Stomach Neoplasms 64Neoplasm Metastasis 64Leukemia, Lymphocytic, Chronic, B-Cell 62Colonic Neoplasms 60Leukemia, Myeloid, Acute 53Uterine Cervical Neoplasms 50Recurrence 49Liver Neoplasms 46Lymphoma, Follicular 45Lymphoma 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 39Esophageal Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 35Head and Neck Neoplasms 35Lymphoma, Non-Hodgkin 34

Interventions

vandetanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Carcinoma, Medullary × Clear all
NCT01945762 2024-12-18

Caprelsa104

Sanofi

Completed
31 enrolled

Aggression, Carcinoma, Medullary

NCT06079723 2023-10-12

A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study

Power Life Sciences Inc.

Not yet recruiting
500 enrolled

Carcinoma, Medullary

NCT01511393 2023-06-13

An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)

Novo Nordisk A/S

Enrolling by invitation
6,750 enrolled

Diabetes Mellitus, Diabetes Mellitus, Type 2, Carcinoma, Medullary

NCT02109250 2017-05-02

CaprelsaReg

Sanofi

Completed
10 enrolled

Carcinoma, Medullary

NCT01757470 2016-08-31

Vandetanib Risk Minimisation Effectiveness

Sanofi

Completed
12 enrolled

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡